Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a challenging target for immunotherapy because it has an immunosuppressive tumor microenvironment. Neoadjuvant chemoradiotherapy can increase tumor-infiltrating lymphocyte (TIL) density, which may predict overall survival (OS). We hypothesized t...

Descripción completa

Detalles Bibliográficos
Autores principales: Katz, Matthew H G, Petroni, Gina R, Bauer, Todd, Reilley, Matthew J, Wolpin, Brian M, Stucky, Chee-Chee, Bekaii-Saab, Tanios S, Elias, Rawad, Merchant, Nipun, Dias Costa, Andressa, Lenehan, Patrick, Cardot-Ruffino, Victoire, Rodig, Scott, Pfaff, Kathleen, Dougan, Stephanie K, Nowak, Jonathan Andrew, Varadhachary, Gauri R, Slingluff, Craig L, Rahma, Osama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693876/
https://www.ncbi.nlm.nih.gov/pubmed/38040420
http://dx.doi.org/10.1136/jitc-2023-007586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693876/
https://www.ncbi.nlm.nih.gov/pubmed/38040420
http://dx.doi.org/10.1136/jitc-2023-007586

Ejemplares similares